VTX-2735 is under clinical development by Ventyx Biosciences and currently in Phase I for Unspecified Cardiovascular Disorders. According to GlobalData, Phase I drugs for Unspecified Cardiovascular Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VTX-2735 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VTX-2735 overview
VTX-2735 is under development for the treatment of systemic inflammatory diseases, recurrent pericarditis, cryopyrin-associated periodic syndrome (CAPS) including familial cold autoinflammatory syndrome (familial cold urticaria) and unspecified cardiovascular disorders. It is administered through oral route in the form of suspension. The drug candidate acts by targeting NACHT, LRR and PYD domains-containing protein 3 (NLRP3).
Ventyx Biosciences overview
Ventyx Biosciences is a clinical stage biopharmaceutical company focused on developing oral medicines for patients suffering with autoimmune and inflammatory disorders. The company is headquartered in San Diego, California, the US.
For a complete picture of VTX-2735’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
